© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 24, 1854-1862,
December 18, 2002
© 2002 Oxford University Press
ARTICLE |
Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin
Affiliations of authors: P. Nangia-Makker, V. Hogan, S. Baccarini, L. Tait, A. Raz, Wayne State University, School of Medicine, and Department of Pathology, Karmanos Cancer Institute, Detroit, MI; Y. Honjo, Wayne State University, School of Medicine, Department of Pathology, Karmanos Cancer Institute, Detroit, and Department of Otolaryngology, Nishi Nihon Hospital, and Nippon Telegraph & Telephone Corporation, Osaka, Japan; R. Bresalier, Department of Gastrointestinal Medicine and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston.
Correspondence to: Avraham Raz, Ph.D., 110 E. Warren Ave., Detroit, MI 48201 (e-mail: raza{at}kci.wayne.edu).
Background: The role of dietary components in cancer progression and metastasis is an emerging field of clinical importance. Many stages of cancer progression involve carbohydrate-mediated recognition processes. We therefore studied the effects of high pH- and temperature-modified citrus pectin (MCP), a nondigestible, water-soluble polysaccharide fiber derived from citrus fruit that specifically inhibits the carbohydrate-binding protein galectin-3, on tumor growth and metastasis in vivo and on galectin-3-mediated functions in vitro. Methods: In vivo tumor growth, angiogenesis, and metastasis were studied in athymic mice that had been fed with MCP in their drinking water and then injected orthotopically with human breast carcinoma cells (MDA-MB-435) into the mammary fat pad region or with human colon carcinoma cells (LSLiM6) into the cecum. Galectin-3-mediated functions during tumor angiogenesis in vitro were studied by assessing the effect of MCP on capillary tube formation by human umbilical vein endothelial cells (HUVECs) in Matrigel. The effects of MCP on galectin-3-induced HUVEC chemotaxis and on HUVEC binding to MDA-MB-435 cells in vitro were studied using Boyden chamber and labeling assays, respectively. The data were analyzed by two-sided Student’s t test or Fisher’s protected least-significant-difference test. Results: Tumor growth, angiogenesis, and spontaneous metastasis in vivo were statistically significantly reduced in mice fed MCP. In vitro, MCP inhibited HUVEC morphogenesis (capillary tube formation) in a dose-dependent manner. In vitro, MCP inhibited the binding of galectin-3 to HUVECs: At concentrations of 0.1% and 0.25%, MCP inhibited the binding of galectin-3 (10 µg/mL) to HUVECs by 72.1% (P = .038) and 95.8% (P = .025), respectively, and at a concentration of 0.25% it inhibited the binding of galectin-3 (1 µg/mL) to HUVECs by 100% (P = .032). MCP blocked chemotaxis of HUVECs toward galectin-3 in a dose-dependent manner, reducing it by 68% at 0.005% (P<.001) and inhibiting it completely at 0.1% (P<.001). Finally, MCP also inhibited adhesion of MDA-MB-435 cells, which express galectin-3, to HUVECs in a dose-dependent manner. Conclusions: MCP, given orally, inhibits carbohydrate-mediated tumor growth, angiogenesis, and metastasis in vivo, presumably via its effects on galectin-3 function. These data stress the importance of dietary carbohydrate compounds as agents for the prevention and/or treatment of cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Park, L. A Brinton, A. F Subar, A. Hollenbeck, and A. Schatzkin Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health-AARP Diet and Health Study Am. J. Clinical Nutrition, September 1, 2009; 90(3): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. IURISCI, A. CUMASHI, A. A. SHERMAN, Y. E. TSVETKOV, N. TINARI, E. PICCOLO, M. D'EGIDIO, V. ADAMO, C. NATOLI, G. A. RABINOVICH, et al. Synthetic Inhibitors of Galectin-1 and -3 Selectively Modulate Homotypic Cell Aggregation and Tumor Cell Apoptosis Anticancer Res, January 1, 2009; 29(1): 403 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Peng, H. Y. Wang, Y. Miyahara, G. Peng, and R.-F. Wang Tumor-Associated Galectin-3 Modulates the Function of Tumor-Reactive T Cells Cancer Res., September 1, 2008; 68(17): 7228 - 7236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kumar and S. L. Deutscher 111In-Labeled Galectin-3-Targeting Peptide as a SPECT Agent for Imaging Breast Tumors J. Nucl. Med., May 1, 2008; 49(5): 796 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Thijssen, S. Hulsmans, and A. W. Griffioen The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial Cells Am. J. Pathol., February 1, 2008; 172(2): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. J. L. Thijssen, F. Poirier, L. G. Baum, and A. W. Griffioen Galectins in the tumor endothelium: opportunities for combined cancer therapy Blood, October 15, 2007; 110(8): 2819 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Jackson, T. M Dreaden, L. K Theobald, N. M Tran, T. L Beal, M. Eid, M. Y. Gao, R. B Shirley, M. T Stoffel, M V. Kumar, et al. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure Glycobiology, August 1, 2007; 17(8): 805 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, P. Neri, D. He, N. Mitsiades, P. Richardson, Y. Chang, J. Schindler, et al. A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells Cancer Res., September 15, 2005; 65(18): 8350 - 8358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Irie, A. Yamauchi, K. Kontani, M. Kihara, D. Liu, Y. Shirato, M. Seki, N. Nishi, T. Nakamura, H. Yokomise, et al. Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2962 - 2968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zou, V. V. Glinsky, L. A. Landon, L. Matthews, and S. L. Deutscher Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion Carcinogenesis, February 1, 2005; 26(2): 309 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P.V. Shekhar, P. Nangia-Makker, L. Tait, F. Miller, and A. Raz Alterations in Galectin-3 Expression and Distribution Correlate with Breast Cancer Progression: Functional Analysis of Galectin-3 in Breast Epithelial-Endothelial Interactions Am. J. Pathol., December 1, 2004; 165(6): 1931 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsutsumi, T. Yanagawa, T. Shimura, H. Kuwano, and A. Raz Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis Clin. Cancer Res., November 15, 2004; 10(22): 7775 - 7784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimura, Y. Takenaka, S. Tsutsumi, V. Hogan, A. Kikuchi, and A. Raz Galectin-3, a Novel Binding Partner of {beta}-Catenin Cancer Res., September 15, 2004; 64(18): 6363 - 6367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Fukushi, I. T. Makagiansar, and W. B. Stallcup NG2 Proteoglycan Promotes Endothelial Cell Motility and Angiogenesis via Engagement of Galectin-3 and {alpha}3{beta}1 Integrin Mol. Biol. Cell, August 1, 2004; 15(8): 3580 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. V. Glinskii, J. R. Turk, K. J. Pienta, V. H. Huxley, and V. V. Glinsky Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells J. Physiol., January 1, 2004; 554(1): 89 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. Glinsky, G. V. Glinsky, O. V. Glinskii, V. H. Huxley, J. R. Turk, V. V. Mossine, S. L. Deutscher, K. J. Pienta, and T. P. Quinn Intravascular Metastatic Cancer Cell Homotypic Aggregation at the Sites of Primary Attachment to the Endothelium Cancer Res., July 1, 2003; 63(13): 3805 - 3811. [Abstract] [Full Text] [PDF]
|
|